NeuroScientific Biopharmaceuticals Limited (NSB.AX)

0.0480 -0.0040 (-7.69%) At close: 03:36PM AEST

NeuroScientific Biopharmaceuticals Limited

85 Forrest Street
Suite 5
Cottesloe, WA 6011
Australia
61 8 6382 1805
https://www.neuroscientific.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.	CFO & Company Secretary	119.16k	N/A	N/A
Dougal Thring	Chief Operating Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.

Corporate governance

NeuroScientific Biopharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.